O	0	10	Randomised
O	11	21	controlled
O	22	27	trial
O	28	37	comparing
B-intervention	38	50	hypnotherapy
O	51	57	versus
B-control	58	68	gabapentin
O	69	72	for
O	73	76	the
O	77	86	treatment
O	87	89	of
B-condition	90	93	hot
I-condition	94	101	flashes
O	102	104	in
O	105	111	breast
O	112	118	cancer
O	119	128	survivors
O	128	129	:
O	130	131	a
O	132	137	pilot
O	138	143	study
O	143	144	.

O	145	147	To
O	148	155	compare
O	156	159	the
O	160	168	efficacy
O	169	171	of
O	172	184	hypnotherapy
O	185	191	versus
O	192	202	gabapentin
O	203	206	for
O	207	210	the
O	211	220	treatment
O	221	223	of
O	224	227	hot
O	228	235	flashes
O	236	238	in
O	239	245	breast
O	246	252	cancer
O	253	262	survivors
O	262	263	,
O	264	267	and
O	268	270	to
O	271	279	evaluate
O	280	283	the
O	284	295	feasibility
O	296	298	of
O	299	309	conducting
O	310	311	a
O	312	320	clinical
O	321	326	trial
O	327	336	comparing
O	337	338	a
O	339	343	drug
O	344	348	with
O	349	350	a
O	351	364	complementary
O	365	367	or
O	368	379	alternative
O	380	386	method
O	387	388	(
O	388	391	CAM
O	391	392	)
O	392	393	.

O	394	405	Prospective
O	406	416	randomised
O	417	422	trial
O	422	423	.

O	424	430	Breast
O	431	437	health
O	438	444	centre
O	445	447	of
O	448	449	a
O	450	458	tertiary
O	459	463	care
O	464	470	centre
O	470	471	.

B-total-participants	472	474	15
B-eligibility	475	480	women
I-eligibility	481	485	with
I-eligibility	486	487	a
I-eligibility	488	496	personal
I-eligibility	497	504	history
I-eligibility	505	507	of
I-eligibility	508	514	breast
I-eligibility	515	521	cancer
I-eligibility	522	524	or
I-eligibility	525	527	an
I-eligibility	528	537	increased
I-eligibility	538	542	risk
I-eligibility	543	545	of
I-eligibility	546	552	breast
I-eligibility	553	559	cancer
I-eligibility	560	563	who
I-eligibility	564	572	reported
I-eligibility	573	575	at
I-eligibility	576	581	least
I-eligibility	582	585	one
I-eligibility	586	591	daily
I-eligibility	592	595	hot
I-eligibility	596	601	flash
O	601	602	.

O	603	613	Gabapentin
O	614	617	900
O	618	620	mg
O	621	626	daily
O	627	629	in
O	630	635	three
O	636	643	divided
O	644	649	doses
O	650	651	(
O	651	658	control
O	658	659	)
O	660	668	compared
O	669	673	with
O	674	686	standardised
O	687	699	hypnotherapy
O	699	700	.

O	701	714	Participation
O	715	721	lasted
O	722	723	8
O	724	729	weeks
O	729	730	.

O	731	734	The
O	735	742	primary
O	743	752	endpoints
O	753	757	were
O	758	761	the
B-outcome-Measure	762	768	number
I-outcome-Measure	769	771	of
I-outcome-Measure	772	777	daily
I-outcome-Measure	778	781	hot
I-outcome-Measure	782	789	flashes
O	790	793	and
B-outcome-Measure	794	797	hot
I-outcome-Measure	798	803	flash
I-outcome-Measure	804	812	severity
I-outcome-Measure	813	818	score
I-outcome-Measure	819	820	(
I-outcome-Measure	820	824	HFSS
I-outcome-Measure	824	825	)
O	825	826	.

O	827	830	The
O	831	840	secondary
O	841	849	endpoint
O	850	853	was
O	854	857	the
B-outcome-Measure	858	861	Hot
I-outcome-Measure	862	867	Flash
I-outcome-Measure	868	875	Related
I-outcome-Measure	876	881	Daily
I-outcome-Measure	882	894	Interference
I-outcome-Measure	895	900	Scale
I-outcome-Measure	901	902	(
I-outcome-Measure	902	908	HFRDIS
I-outcome-Measure	908	909	)
O	909	910	.

B-total-participants	911	913	27
O	914	919	women
O	920	924	were
O	925	935	randomised
O	936	939	and
B-total-participants	940	942	15
O	943	944	(
O	944	946	56
O	946	947	%
O	947	948	)
O	949	953	were
O	954	964	considered
O	965	974	evaluable
O	975	978	for
O	979	982	the
O	983	990	primary
O	991	999	endpoint
O	1000	1001	(
O	1001	1002	n
O	1002	1003	=
B-control-participants	1003	1004	8
O	1005	1015	gabapentin
O	1015	1016	,
O	1017	1018	n
O	1018	1019	=
B-intervention-participants	1019	1020	7
O	1021	1033	hypnotherapy
O	1033	1034	)
O	1034	1035	.

O	1036	1039	The
B-outcome	1040	1046	median
I-outcome	1047	1053	number
I-outcome	1054	1056	of
I-outcome	1057	1062	daily
I-outcome	1063	1066	hot
I-outcome	1067	1074	flashes
I-outcome	1075	1077	at
I-outcome	1078	1087	enrolment
O	1088	1091	was
B-cv-cont-median	1092	1093	4
I-cv-cont-median	1093	1094	.
I-cv-cont-median	1094	1095	5
O	1096	1098	in
O	1099	1102	the
O	1103	1113	gabapentin
O	1114	1117	arm
O	1118	1121	and
B-iv-cont-median	1122	1123	5
O	1124	1126	in
O	1127	1130	the
O	1131	1143	hypnotherapy
O	1144	1147	arm
O	1147	1148	.

B-outcome	1149	1153	HFSS
I-outcome	1154	1160	scores
O	1161	1165	were
B-cv-cont-median	1166	1167	7
I-cv-cont-median	1167	1168	.
I-cv-cont-median	1168	1169	5
O	1170	1172	in
O	1173	1176	the
O	1177	1187	gabapentin
O	1188	1191	arm
O	1192	1195	and
B-iv-cont-median	1196	1198	10
O	1199	1201	in
O	1202	1205	the
O	1206	1218	hypnotherapy
O	1219	1222	arm
O	1222	1223	.

B-outcome	1224	1229	After
I-outcome	1230	1231	8
I-outcome	1232	1237	weeks
O	1237	1238	,
O	1239	1242	the
B-outcome	1243	1249	median
I-outcome	1250	1256	number
I-outcome	1257	1259	of
I-outcome	1260	1265	daily
I-outcome	1266	1269	hot
I-outcome	1270	1277	flashes
O	1278	1281	was
O	1282	1289	reduced
O	1290	1292	by
B-cv-cont-median	1293	1295	33
I-cv-cont-median	1295	1296	.
I-cv-cont-median	1296	1297	3
I-cv-cont-median	1297	1298	%
O	1299	1301	in
O	1302	1305	the
O	1306	1316	gabapentin
O	1317	1320	arm
O	1321	1324	and
O	1325	1327	by
B-iv-cont-median	1328	1330	80
I-iv-cont-median	1330	1331	%
O	1332	1334	in
O	1335	1338	the
O	1339	1351	hypnotherapy
O	1352	1355	arm
O	1355	1356	.

O	1357	1360	The
B-outcome	1361	1367	median
I-outcome	1368	1372	HFSS
O	1373	1376	was
O	1377	1384	reduced
O	1385	1387	by
B-cv-cont-median	1388	1390	33
I-cv-cont-median	1390	1391	.
I-cv-cont-median	1391	1392	3
I-cv-cont-median	1392	1393	%
O	1394	1396	in
O	1397	1400	the
O	1401	1411	gabapentin
O	1412	1415	arm
O	1416	1419	and
O	1420	1422	by
B-iv-cont-median	1423	1425	85
I-iv-cont-median	1425	1426	%
O	1427	1429	in
O	1430	1433	the
O	1434	1446	hypnotherapy
O	1447	1450	arm
O	1450	1451	.

B-outcome	1452	1458	HFRDIS
I-outcome	1459	1465	scores
I-outcome	1466	1474	improved
O	1475	1477	by
B-cv-cont-mean	1478	1480	51
I-cv-cont-mean	1480	1481	.
I-cv-cont-mean	1481	1482	6
I-cv-cont-mean	1482	1483	%
O	1484	1486	in
O	1487	1490	the
O	1491	1501	gabapentin
O	1502	1507	group
O	1508	1511	and
O	1512	1514	by
B-iv-cont-median	1515	1517	55
I-iv-cont-median	1517	1518	.
I-iv-cont-median	1518	1519	2
I-iv-cont-median	1519	1520	%
O	1521	1523	in
O	1524	1527	the
O	1528	1540	hypnotherapy
O	1541	1546	group
O	1546	1547	.

O	1548	1553	There
O	1554	1558	were
O	1559	1561	no
O	1562	1575	statistically
O	1576	1587	significant
O	1588	1599	differences
O	1600	1607	between
O	1608	1614	groups
O	1614	1615	.

O	1616	1628	Hypnotherapy
O	1629	1632	and
O	1633	1643	gabapentin
O	1644	1655	demonstrate
O	1656	1664	efficacy
O	1665	1667	in
O	1668	1677	improving
O	1678	1681	hot
O	1682	1689	flashes
O	1689	1690	.

O	1691	1692	A
O	1693	1703	definitive
O	1704	1709	trial
O	1710	1720	evaluating
O	1721	1732	traditional
O	1733	1746	interventions
O	1747	1754	against
O	1755	1758	CAM
O	1759	1766	methods
O	1767	1769	is
O	1770	1778	feasible
O	1778	1779	,
O	1780	1783	but
O	1784	1787	not
O	1788	1795	without
O	1796	1806	challenges
O	1806	1807	.

O	1808	1815	Further
O	1816	1823	studies
O	1824	1829	aimed
O	1830	1832	at
O	1833	1841	defining
O	1842	1850	evidence
O	1850	1851	-
O	1851	1856	based
O	1857	1872	recommendations
O	1873	1876	for
O	1877	1880	CAM
O	1881	1884	are
O	1885	1894	necessary
O	1894	1895	.
O	1896	1910	clinicaltrials
O	1910	1911	.

O	1912	1915	gov
O	1916	1917	(
O	1917	1928	NCT00711529
O	1928	1929	)
O	1929	1930	.
